This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Corbus Pharmaceuticals (CRBP) Stock Moves -1.23%: What You Should Know
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) closed the most recent trading day at $7.23, moving -1.23% from the previous trading session.
Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) closed at $7.18 in the latest trading session, marking a -0.97% move from the prior day.
Is Corbus Pharmaceuticals Holdings (CRBP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CRBP) Outperforming Other Medical Stocks This Year?
Corbus Pharmaceuticals (CRBP) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -36.36% and -3.02%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.
Pacira (PCRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) impresses investors with both earnings and revenue beat in the fourth quarter.
Jazz Pharmaceuticals (JAZZ) Surges: Stock Moves 7.9% Higher
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8%
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) surpasses earnings and sales estimates in the fourth quarter and issues a solid outlook for 2019. Shares rise 8% in after-hours trading.
Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Corbus Pharmaceuticals (CRBP) closed at $7.64, marking a -0.52% move from the previous day.
Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) needs investors to pay close attention to the stock based on moves in the options market lately.
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
by Zacks Equity Research
CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -23.81% and -34.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares rise 6% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Vertex Completes Enrollment in Triple Combination Studies
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.
Vertex Inks Reimbursement Agreement for Orkambi in Australia
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -5.00% and -55.05%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex's Shares Rally as a Rival's CF Candidate Disappoints
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.
4 Best Marijuana Stocks to Play the Green Rush
by Zacks Equity Research
Given the increasing bullish environment, the movement to legalize marijuana has definitely picked up steam. Below are four cannabis-linked stocks that are poised to benefit from legalization.
Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 10% Higher
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) was a big mover last session, as the company saw its shares rise 10% on the day.
Aerie Pharmaceuticals (AERI) Surges: Stock Moves 16.2% Higher
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) was a big mover last session, as the company saw its shares rise more than 16% on the day amid huge volumes.
Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher
by Zacks Equity Research
Flexion Therapeutics (FLXN) shares rose more than 10% in the last trading session, amid huge volumes.
Infinity Pharmaceuticals, Inc. (INFI) in Focus: Stock Moves 12% Higher
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise nearly 12% on the day.